Artasome Therapeutics is a pre-clinical stage company focused on the treatment of innate driven, inflammatory-fibrotic (IDIF) rare diseases associated with significant morbidity and mortality. NLRP3 activation, and resulting inflammasome assembly, plays a critical role in the IDIF disease process and is closely associated with intersitial lung disease (ILD) and numerous autoimmune disorders such as systemic sclerosis. Artasome's drug candidate has been shown to inhibit NLRP3 activation by blocking the binding of NEK7, thereby preventing canonical inflammasome assembly. This has the ability to reduce both chronic inflammation and pulmonary fibrosis, which has been demonstrated in multiple pre-clinical models of rare disease. The company received its first orphan drug designation from FDA for the treatment of idiopathic pulmonary fibrosis (IPF).